Live Breaking News & Updates on Rodryg Ramlau

Stay updated with breaking news from Rodryg ramlau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) -October 23, 2023 at 08:28 am EDT

GALLANT-1: GB1211 Galectin-3 inhibitor plus atezolizumab for first line treatment in patients

. ....

Comunidad Autonoma De Cataluna , France General , Israel General , Rodryg Ramlau , Ashfield Medcomms , Enriqueta Felip , Enric Carcereny , Zahir Rajiwate , Eric Pichon , Biomarcadoresy Medicina , Linda Basse , Chemother Pharmacol , Tariq Sethi , Alison Mackinnon , Pia Jensen , Bertil Lindmark , Patricia Barre , Graham Ross , Triasi Pujol , Vassilios Aslanis , Immunotherapy Medical Institute , Montpellier Regional University Hospital , Hebron University Hospital , University Of Burgundy , Catalan Institute Of Oncology Badalona , Oncology Department ,